Trial Profile
A phase IIa multiple ascending dose study of doxorubicin transferrin conjugate [TRF-DOX] in patients with platinum-resistant ovarian cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2015
Price :
$35
*
At a glance
- Drugs Doxorubicin conjugate (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 17 Apr 2015 New trial record